Background: Patients with chronic kidney disease (CKD) have a high prevalence of cardiovascular disease (CVD). Arterial stiffness plays an important role in the pathogenesis of CVD; however, to date, there have been no reports of the assessment of arterial stiffness in patients at different stages of non-diabetic CKD. Methods: We studied 50 patients with non-diabetic CKD (stages 1 − 5, 5D) receiving medical treatment at Tokyo Women's Medical University. Pulse wave velocity (PWV) was assessed using an applanation tonometer to determine arterial compliance. All current medications were recorded and biochemical parameters were analyzed. Results: Non-diabetic CKD stage 5D patients had a higher PWV, and higher serum levels of C-reactive protein (CRP), Ca, P and intact parathyroid hormone (iPTH) than non-diabetic CKD stage 1 − 5 patients (p 0.03, p 0.009, p 0.006, p 0.00005, and p 0.002, respectably). As compared to nondiabetic CKD stage 1 − 2 patients, patients with non-diabetic CKD stage 3 − 5 were older, and had higher serum levels of P and iPTH and a higher PWV (p 0.0002, p 0.009, p 0.03, and p 0.004). Nephrosclerosis was associated with a higher PWV, higher serum levels of CRP, and a higher prevalence of CVD than patients with CKD of other origins.
(PWV), a standard measure of arterial stiffness, is reportedly a strong independent predictor of the overall and cardiovascular mortality in patients with stage 4 and 5 CKD. A recent study showed a stepwise increase of the PWV from CKD stage 1 to stage 5 5) ; however, patients with diabetic mellitus (DM) were also included in these studies. Vascular stiffness was significantly higher in patients with diabetic nephropathy than in those with glomerulonephritis or nephrosclerosis
Introduction
Many clinical and epidemiological investigations have shown that atherosclerosis and vascular calcification contribute to high cardiovascular mortality in patients with stage 4 and 5 chronic kidney disease (CKD) [1] [2] [3] . Furthermore, patients with CKD stage 5D, which refers to patients with stage 5 CKD on hemodialysis, have a very high prevalence of cardiovascular risk factors, and approximately 40% have clinical coronary artery disease 4) . Aortic pulse wave velocity
Subjects and Methods

Subjects
We studied 50 patients with non-diabetic CKD (stage 1 − 5, 5D) who received medical treatment and follow up from September 2007 to March 2008 at Tokyo Women's Medical University. CKD was diagnosed according to previously described criteria 7) . The Research Ethics Board of Tokyo Women's Medical University approved the study protocol. All patients gave written informed consent to participate in the study. The causal disease was chronic glomerulonephritis in 30 cases (60.0%), nephrosclerosis in 15 (30.0%), interstitial nephritis in 2 (4.0%), and polycystic kidney disease, amyloid kidney and gouty kidney in one patient each. We excluded patients with peripheral arterial disease. We used PWV as a marker of arterial stiffness. PWV was measured using an automatic waveform analyzer (form PWV/ABl; Colin, Co., Ltd., Komaki, Japan) as described previously 8) . We measured the brachial-ankle pulse wave velocity (ba PWV). All individuals were examined after they had rested in the supine position for at least 5 minutes. The ba PWV value reflects the degree of stiffness of the central arteries, and ba PWV has been shown to be well correlated with the aortic PWV measured using a catheter tip with a pressure manometer 9) . Systolic and diastolic blood pressure (SBP, DBP), body mass index (BMI), estimated glomerular filtration rate (eGFR) 10) , serum total cholesterol (TC), triglycerides (TG) and high density lipoprotein cholesterol (HDLC), fasting blood glucose (FBG), and serum Ca, P, intact parathyroid hormone (iPTH) and C-reactive protein (CRP) were measured at the time of measuring the PWV. The diagnosis of CVD (history of myocardial infarction, angina pectoris, stroke or peripheral arterial occlusive disease) and information on whether the patients were receiving antihypertensive medication and/or statins were obtained from the medical charts and analyzed. Thirty-six patients (72.0%) were taking antihypertensive medications, including 27 (54.0%) on angiotensin receptor blockers (ARBs), 22 (44.0%) on calcium-channel blockers, 11 (22.0%) on or , receptor blockers and 3 on angiotensinconverting enzyme inhibitors. Eighteen patients (36%) had received statins.
Statistical Analysis
All values were expressed as the means standard deviation, unless otherwise specified. Differences between two groups were determined by the t test or 2 test. Correlations between the eGFR and mean PWV were determined by Pearson's correlation coefficient. Multiple linear regression analysis was used to evaluate the contribution of each risk factor to the mean PWV. P values of 0.05 were considered significant.
Results
Of the 50 patients, 11 were on hemodialysis (CKD stage 5D), 26 had CKD stage 3, 4 or 5, and 13 had CKD stage 1 or 2. Overall, 7 (14.0%) patients had CVD. Although there were no CVD patients in the CKD stage 1 or 2 group, 7 of the 37 patients with CKD stages 3, 4, 5 or 5D (18.9%) had CVD.
To clarify arterial stiffness in hemodialysis patients, we divided the subjects into two groups, namely, the non-hemodialysis group (CKD stages 1 − 5) and the hemodialysis group (CKD stage 5D). The non-hemodialysis group included 39 patients with a mean age of 51.8 21.5 (male: 25, female: 14) years at the time of the PWV measurement, and the hemodialysis group included 11 patients with a mean age of 55.7 17.0 years (male: 6, female: 5). The hemodialysis group had a higher PWV than the non-hemodialysis group (p 0.009) ( Table 1) . As compared with the values in the non-hemodialysis group, the hemodialysis group had increased serum levels of CRP, P, TC and iPTH, and a higher prevalence of CVD (p 0.002, p 0.006, p 0.0009, p 0.00005, and p 0.03, respectively). There were no significant differences in SBP, DBP, BMI, TG, HDL-C, Ca, or the frequency of treatment with an ARB or statin between non-hemodialysis and hemodialysis groups.
Next, we divided non-hemodialysis patients into two groups; one consisting of CKD stage 1, 2 patients and the other of CKD stage 3 − 5 patients ( Table 2) . PWV was significantly higher in the CKD stage 3 − 5 group (p 0.04) than in the CKD stage 1, 2 group. As compared with the findings in the CKD stage 1, 2 group, the mean age and serum iPTH levels were higher in the CKD stage 3 − 5 group (p 0.0002 and p 0.03).
A scatter-plot of the relations between PWV and eGFR is presented as Fig. 1 . We found a significant negative correlation between PWV and eGFR (p 0.0003, r 0.50). In addition, we compared the parameters between patients with nephrosclerosis and patients with CKD of other origins. As shown in Table 3 , the prevalence of CVD, serum CRP, and PWV were higher in the nephrosclerosis group than in the other group.
We assessed whether treatment with an ARB or statin might improve PWV as an indicator of arterial stiffness; however, no effect of treatment with an ARB or statin on PWV (data not shown) was observed in this retrospective study.
We performed multivariate regression analysis to identify determinants of PWV using all factors, and found that increased PWV was independently associated with age, serum CRP, and presence of CVD, eGFR and nephrosclerosis (p 0.0002, p 0.0005, p 0.004, p 0.02 and p 0.04, respectively) ( Table 4) . 
Discussion
In the present study, we examined arterial stiffness in non-diabetic CKD patients using aortic PWV, a standard measure of arterial stiffness. Arterial stiffness plays an important role in the pathogenesis of CVD in patients as well as in those without CKD 11, 12) . The association of CKD with the risk of adverse outcomes is strongly related to CVD and its risk factors 13) . A previous study demonstrated correlations of PWV with age, eGFR, CVD and diabetes, consistent with the results of our analysis 5) . Decreased eGFR was shown to have an independent, inverse association with arterial stiffness, as reflected by the increased PWV in patients with CKD 14) . Because arterial stiffness increases with advancing age, it is possible that the difference in age between CKD 1 − 2 and 3 − 5 affected the difference of PWV in this study. Furthermore, PWV has been reported as an independent contributor to coronary artery calcification, along with the aortic calcification index 15) . The degree of decrease in the eGFR may indicate the severity of underlying disease in such conditions as diabetes and hypertension. Diabetic and hypertensive subjects have been demonstrated to have a higher PWV 16) . Insulin resistance is associated with increased arterial stiffness and hemodynamic alterations in the common carotid artery 17, 18) . Insulin resistance reportedly induces sympathetic stimulation, endothelial dysfunction, aldosterone activation, renal sodium absorption, activation of the renin-angiotensin-aldosterone system, release of advanced glycation end-products and lipid peroxidation, which result in vascular remodeling [19] [20] [21] . Decreased renal function may increase the PWV through insulin resistance; therefore, to examine arterial stiffness without the confounding effect of insulin resistance, we excluded patients with diabetes mellitus, and blood pressure was routinely maintained at a normal level with antihypertensive medication. We thus found that non-diabetic CKD also promotes the development of arterial stiffness. There is growing evidence that chronic inflammation plays a role in the pathogenesis of atherosclerosis. Data from several prospective studies have demonstrated that elevation of serum levels in acute-phase reactant CRP predicts an increased risk of future cardiovascular events in a wide range of clinical populations 22, 23) . We identified serum CRP as an independent contributor to high PWV in non-diabetic CKD patients. Also, we examined the severity of vascular calcification and showed that serum iPTH levels in CKD stage 3 − 5 and hemodialysis patients were elevated as compared with those in CKD stage 1 − 2 patients. Categorization of patients into CKD stage 1, 2 and 3 − 5 was based on the cutoff value of 60 mL/min/1.73 m 2 , because this represents a dec- rement to approximately half of the normal renal function, and because its use avoids misclassification of many older individuals who may have only a mild reduction of GFR 24) . This is consistent with recently published data which showed that patients with poor control of Ca and P were more likely to develop progressive vascular calcification 25) , which has profound effects on cardiovascular function. It is associated with reduced arterial compliance, as illustrated by the results of multivariate analysis of our present data, which in turn, appears to be associated with an altered systemic hemodynamic state. Vascular calcification and increased arterial stiffness are associated with reduced baroreflex sensitivity, potentially producing short-term dysregulation of blood pressure 26) . Although, in our study, treatment with ARBs or statins was not associated with improvement in the severity of arterial stiffness in non-diabetic CKD patients, recent studies have found that longterm blockade of the renin-angiotensin system might prevent increased arterial stiffness and vascular calcification and thereby reduce the incidence of cardiovascular events [27] [28] [29] . Thus, evaluation of the effects of treatment with ARBs or statins should include a longer follow-up period for precise determination of the significance of arterial stiffness and vascular calcification.
Furthermore, a significant increase of the PWV and prevalence of CVD was noted in nephrosclerosis patients as compared with patients with other nondiabetic renal diseases in our study. In Japan, the 10-year survival of patients with end-stage renal disease (ESRD) with nephrosclerosis was approximately half of that of ESRD patients with glomerulonephritis. Nephrosclerosis is an increasingly common cause of ESRD 30) and aggressive management is necessary to prevent the development of ESRD.
In conclusion, we demonstrated increased arterial stiffness in non-diabetic CKD patients. We showed a stepwise increase in arterial stiffness with increasing disease severity stage in patients with CKD without diabetes mellitus. Also, we showed that nephrosclerosis increases the risk of CVD. Multivariate analysis identified the age, CRP, eGFR, and presence of CVD and nephrosclerosis as independent risk factors for increased PWV. Although ARBs and statins did not influence PWV in this study, investigation with a longer follow-up period is required for precise evaluation of the long-term effects of ARBs and statins on PWV.
